Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).

RADIATION

Radiotherapy

PROCEDURE

Radiofrequency ablation

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02437071 - Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter